Proteasome-mediated degradation of IκBα and processing of p105 in Crohn disease and ulcerative colitis
J. Clin. Invest. Alexander Visekruna, et al. 116:3195 doi:10.1172/JCI28804 [
Go to this article.]
Figure 2Proteolytic activity of proteasomes in IBD patients. (
A–
C) Enzymatic activity of 20S proteasomes purified from colonic mucosa of CD patients (filled squares), UC patients (triangles), and control patients (circles) was measured by cleavage of fluorogenic peptide substrates. Control reaction was performed in the presence of the proteasome inhibitor MG132 (open squares). Data are expressed as means ± SEM. (
n = 5). Statistical significance was determined by 1-way ANOVA (chymotrypsin- and caspase-like activity,
P < 0.001; trypsin-like activity,
P = 0.114). (
D) Western blot of lysates from inflamed intestinal mucosa of CD patients, UC patients, and controls was stained for the proteasomal immunosubunit β1 and β-actin. (
E) Quantitative analysis of the proteasomal β1/β-actin protein ratio was performed using AIDA Image Analyser software (version 4.0.3; Raytest). Data represent means ± SEM; CD (
n = 10), UC (
n = 10), and controls (
n = 9). *
P < 0.05, Student’s
t test (
n = 9–10).
